| Identification | Back Directory | [Name]
L-Arginine, L-asparaginyl-L-α-glutamyl-L-asparaginyl-L-isoleucyl-L-threonyl-L-valyl-L-prolyl-L-α-aspartyl-L-threonyl-L-lysyl-L-valyl-L-asparaginyl-L-phenylalanyl-L-tyrosyl-L-alanyl-L-tryptophyl-L-lysyl- | [CAS]
915091-83-7 | [Synonyms]
L-Arginine, L-asparaginyl-L-α-glutamyl-L-asparaginyl-L-isoleucyl-L-threonyl-L-valyl-L-prolyl-L-α-aspartyl-L-threonyl-L-lysyl-L-valyl-L-asparaginyl-L-phenylalanyl-L-tyrosyl-L-alanyl-L-tryptophyl-L-lysyl- | [Molecular Formula]
C100H151N27O29 | [MOL File]
915091-83-7.mol | [Molecular Weight]
2195.43 |
| Hazard Information | Back Directory | [Uses]
Epobis, a dendrimeric peptide, is a recombinant form of erythropoietin. Epobis is a potent erythropoietin receptor agonist. Epobis promotes neuritogenesis in primary motoneurons. Epobis decrease TNF release and crosses the blood-brain barrier. Epobis has anti-inflammatory and memory enhancing properties[1]. | [in vivo]
Epobis (10 mg/kg; i.h.; Wistar rats) can cross the blood-brain barrier (BBB)[1].
Epobis (10 mg/kg; i.h.) has an anti-inflammatory effect in mice of multiple sclerosis model[1].
Epobis (10 mg/kg; i.h.; old (>18 month) rats and in rats experiencing early stage AD) improves social memory[1].
| Animal Model: | Wistar rats (200 g)[1] | | Dosage: | 10 mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Had detectable already 15?min after administration and remained detectable in the blood for at least 24?h. |
| Animal Model: | Wistar rats with multiple sclerosis model (200 g)[1] | | Dosage: | 10 mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Had no significant effects on the weight changes or the survival of experimental autoimmune encephalomyelitis (EAE) animals. |
| Animal Model: | Old (>18 month) rats and in rats experiencing early stage AD[1] | | Dosage: | 10 mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Had significantly lower than that of vehicle-treated animals. |
| [References]
[1] Dmytriyeva O, et, al. Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects. Mediators Inflamm. 2016;2016:1346390. DOI:10.1155/2016/1346390 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|